ETANERCEPT (Enbrel; Immunex Corporation; Seattle, Wash) is a biologic response modifier indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs. The safety and efficacy of etanercept have been assessed in multiple randomized, double-blind, placebo-controlled studies.1- 4 These studies demonstrated a significant response to therapy with etanercept at 3 and 6 months compared with placebo and/or methotrexate. In phase II and phase III clinical trials, injection-site reactions (ISRs) occurred significantly more often and were reported in up to 49% of patients in the etanercept-treated group.3,4 In this brief report, we evaluate the pathological findings of skin biopsies from an etanercept-associated ISR in a patient with rheumatoid arthritis.
Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-Associated Injection-Site Reactions. Arch Dermatol. 2000;136(4):556–557. doi:
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.